Marketing content

Why invest in Ansana?

1

A structural hospital problem with a large economic impact

Ansana targets a well-documented bottleneck: hospitals often do not know where surgical instrument sets are or whether they have been cleaned, sterilised and assembled for use. Better instrument-flow visibility helps hospitals unlock existing surgical capacity and improve staff productivity without adding new operating rooms or hiring additional staff.

Learn more
2

Experienced founders and specialised investors

The core team combines experience in healthcare, medical devices, commercial hospital sales and over 30 years of industrial R&D. Ansana is backed by NLC Health Impact Fund, Stepping Stone Fund, Tanner Health / Healthliant and active business angels.

Learn more
3

Technology and intellectual‑property backing

Ansana's platform combines smart sensors, real-time localisation and AI-powered analytics and optimization.  The technology is supported by an exclusive worldwide licence to Stryker patents plus additional patent filings. This intellectual‑property base strengthens the company's differentiation and may be relevant for future strategic partners or acquirers.

Learn more
4

Clear use of funds and milestone focus

The proceeds of this round are allocated to three clear priorities: completing the first‑generation product, executing the US pilot and building a focused commercial pipeline. Each euro raised has a defined purpose, with a specific milestone the company aims to reach before the next funding round.

Learn more
5

Tanner Health pilot as the central “proof point”

Through the Innovation Participation Agreement with Tanner Health and Healthliant, Ansana aims to show that its system works in daily hospital operations and demonstrate measurable short to long term cost and capacity improvements. This “Tanner proof point” is the main outcome the company wants to achieve with this round.

Learn more
6

Investing on the same terms as existing shareholders

Ansana is raising a seed‑extension at the same share price and share class as the September 2025 seed round. Existing investors have committed around €400,000* as anchor investments, and Invesdor investors participate alongside them on the same economic terms.

Learn more

* According to the liquidity planning of Ansana, at least €200,000 of the €400,000 minimum threshold will be available when the Invesdor round closes. The remaining funds will have been disbursed earlier by the anchor investors and used by Ansana for ongoing operations.

Your investment made under the Regulation (EU) 2020/1503 of the European Parliament and of the Council is not protected by the deposit guarantee schemes etablished under Directive 2024/49/EU (Deposit Guarantee Schemes Directive). Your investment is also not protected by the investor compensation schemes established under Directive 97/9/EC (Investor Compensation Schemes Directive).

Invest

First name last name, position

“In many hospitals, operating room throughput is limited and there are long waiting times for surgeries not because of a lack of surgeons or insufficient operating room capacity, but because of many manual tasks added activities for hospital staff and overall inefficient processes.  Further, the right instrument sets are often not available or ready at the appropriate time resulting in delays. With Ansana we give operating rooms and sterile processing teams real-time insight  and eliminate unnecessary work, while structurally improving hospital processes. This funding round enables us to complete our first-generation platform and prove it in daily use at Tanner Health in the United States, creating a strong reference case for broader roll-out and strategic partnerships. We invite investors who share this vision to join us as shareholders in the next phase of Ansana's journey.”

Dominique Surinx, CEO and co‑founder of Ansana

Investment information

Days to invest:
21
Investing round ends:
26/10/2026
Type:
Equity offering
Invested so far:
€411,612.84
Equity offered:
10.60 – 15.71 %
Price per share:
€27.54
min investment 10 shares
Transaction costs:
1.50 %
Number of existing shares:
193,618
Fully diluted shares:
214,392
Pre-money valuation:
€5,904,355.68
Maximum issue size:
€1,100,223
Offered units:
39,950
Broker:
Oneplanetcrowd International B.V
License:
ECSPR
Note on warrants and valuation: Ansana B.V. has granted 13,359 warrants at an exercise price of €18.49. The fully diluted pre‑money valuation is calculated using the treasury stock method, which results in 4,390 net additional shares from these warrants and a fully diluted share count of 214,392 shares.

About Ansana

Ansana: Problem, Solution and Market

Problem

Surgical capacity held back by invisible instrument flows

The operating room is the main driver for hospital revenue and profit, however, sterile processing of surgical instruments is significantly limiting operating room throughput.  Hospitals rely on thousands of reusable instruments moving between operating rooms and sterile processing. These flow are still managed with manual scanning, phone calls and  very fragmented software systems, resulting in practically no visibility and poor service.

 This leads to delayed procedures, avoidable search time and excess inventory.

According to management, bottlenecks in sterile processing alone can reduce operating-room throughput by around 5–15% in larger hospitals. For a hospital with 20 or more operating rooms, this can represent a potential annual profit impact of USD 5–20 million, depending on the type and volume of procedures performed.

Solution

Real-time, AI powered visibility for surgical instruments

Ansana offers a hardware-enabled software platform that gives hospitals a live view of their surgical instrument sets. Smart sensor modules track each tray's location and processing status as it moves between operating rooms and sterile processing departments. The software links this information to the surgery schedule, so teams can see which sets are ready, which are delayed and where action is needed.

The system works as a digital layer on top of existing hospital tools, rather than replacing them. This keeps implementation straightforward and allows hospitals to adopt the platform without overhauling existing infrastructure.

Further, the hospitals benefit from the AI-powered optimization layer, which uses data sets from all global implementations for benchmarking and continuous process optimization.

Business model

Hardware-enabled subscriptions for hospitals

Ansana plans to earn revenue through long-term contracts with hospitals and health systems. Each contract combines an upfront technology and installation fee with recurring annual subscription fees for software, support and ongoing hardware use.

Management currently models a standard five-year contract of about €820,000 for an average hospital with 18 operating rooms, with annual recurring revenue of around €107,000 per site. These figures are planning assumptions and are not yet based on signed commercial contracts.

Market

A growing surgical market with rising capacity needs

The global surgical and perioperative-care market is estimated at around €3 trillion and is expected to grow further as populations age and more conditions are treated with surgery. Hospitals face increasing procedural  volumes while struggling to add new operating rooms or qualified staff.

Ansana focuses primarily on the United States, where large hospital networks run many operating rooms and sterile processing departments and where the financial impact of improved throughput is particularly strong. The US market combines high labour costs, scale and urgency in a way that makes the economic case for Ansana's solution most compelling.

Competitors

From scan-based tracking to real-time instrument control

Today, many hospitals rely on barcode or radio-frequency tag scanning, software from sterilisation-equipment suppliers and hospital planning systems, supported by manual checks and phone calls. These tools record certain manual check points in the reprocessing flow, but do not capture individual process steps and their proper execution and do not connect these steps  into a live, end-to-end picture..

Ansana positions itself as a real-time digital layer on top of these existing systems, bringing together tray location, processing status and surgery priorities in one view for operating rooms and sterile processing teams. Rather than replacing current tools, the platform connects and enriches them.

Impact

Better use of existing surgical capacity

Ansana's goal is to help hospitals treat more patients with the infrastructure and staff they already have. Surgery schedules can be optimized and operating room throughput increased when reprocessing of instruments can be optimized and staff efficiency increased. Additionally, execution is improved w[NH7.1]hen instrument sets reach the right place at the right time, operating rooms can start more procedures on schedule and sterile processing teams spend less time on avoidable manual work and searching.

The company measures its contribution to healthcare access mainly through the number of patients whose surgical care pathways are supported by hospitals using the Ansana platform. Ansana aligns this ambition with UN Sustainable Development Goal 3, Good Health and Well-being.

Beyond operational efficiency, Ansana's longer-term ambition is to contribute to patient safety. The Gen 2 platform is designed to support sterility monitoring and quality-release functionality, with the goal of reducing risks associated with inadequately processed surgical instruments, including surgical site infections.

SDG 3: Good health and well-being
SDG 3
Good health and well-being

First customer and commercial pipeline

Ansana has signed an Innovation Participation Agreement with Tanner Health and Healthliant, one of the largest independent health systems in the southeastern United States. The agreement structures a pilot and commercialisation path: Tanner hosts the Gen 1 system in a live hospital environment, and a successful pilot creates a path to a commercial contract with a minimum value of USD 1.0 million*. Ansana and Tanner have jointly modelled that network-level sterile processing optimisation could reduce processing costs from more than €300 per tray to €60–70 per tray, representing a potential annual saving of around €5 million across the Tanner network by 2030.

Additionally Ansana’s platform would facilitate Tanner’s strategic surgical revenue growth of USD 120 million* per year over a period of 5 years.

Beyond Tanner, Ansana has built an active commercial pipeline of 304 connections and 22 sales leads. The ten most advanced opportunities represent an unweighted pipeline value of €7.05 million. Tanner is expected to serve as the key reference case for converting this pipeline into contracts.

Tanner — processing cost reduction
>€300 → €60–70

Per tray, jointly modelled with Tanner Health

Potential annual saving — Tanner network
€5 million

Projected by 2030 across the Tanner network

Minimum commercial contract value
USD 1.0 million

On successful completion of the Tanner pilot

Broader pipeline — unweighted value
€7.05 million

10 advanced opportunities across the commercial pipeline

*Note: Tanner-related figures are stated in US dollars, reflecting the currency of the underlying commercial agreements with a US health system.

How it works

Gen 1 — Available now

Workflow management and real-time visibility

Smart sensor modules attached to instrument trays communicate with fixed readers at each point in the reprocessing flow — soiled storage, washing, assembly, packaging, steam sterilisation and sterile storage. The software links this data to the surgery schedule, giving teams a live view of where every set is and which trays need attention first. Gen 1 can be deployed commercially without external medical-device clearance and works as an overlay on existing hospital infrastructure. No existing equipment needs to be replaced.

Gen 2 — In development

Regulated quality release and sterility monitoring

Gen 2 builds on the Gen 1 foundation by adding process-parameter sensing, sterility monitoring and quality-release functionality. This allows hospitals to make regulated claims about instrument readiness and, ultimately, patient safety. Gen 2 is being developed as a regulated medical device under ISO 13485, with a US FDA 510(k) clearance pathway targeted for 2029.

Product roadmap

Ansana's platform follows a deliberate two-generation strategy. Gen 1 focuses on workflow management and operational efficiency. Because it makes no regulated clinical claims, it can be deployed commercially without external medical-device clearance, which means earlier revenue and a validated customer base before entering the regulated market. Gen 2 builds on that foundation, adding sterility monitoring, process-parameter sensing and quality-release functions as a regulated medical device, with FDA clearance targeted for 2029. The current round is focused on the critical step between these two phases: proving Gen 1 in daily use at Tanner Health.

Gen 1 — Workflow management
Alpha and endurance testing passed
Completed
Tanner Health agreement signed
Completed
Seed-extension round and pilot preparation
Now — Q4 2026 You are here
Gen 1 development complete
Q1 2027
Tanner pilot complete
Q2 2027 Key proof point
US market launch
Q3–Q4 2027
Gen 2 — Regulated quality release
Gen 2 development complete
Q1 2029
FDA clearance
Q4 2029
Stage and risk: Ansana is at an early stage. The company is pre-revenue and the Gen 1 system has not yet been deployed in a live hospital environment, although prototypes have been tested extensively in several clinical environments. The Tanner pilot is the central near-term milestone and its successful completion is not guaranteed. Investors should be aware that both technical and commercial risks remain material at this stage.

Management

Ansana's management team is supported by an advisory board with experience in large medtech companies including Philips and B. Braun, quality and regulatory affairs for medical devices, and clinical surgery. This advisory network strengthens the team's ability to navigate hospital adoption, regulatory preparation and strategic partnerships.

Dominique Surinx CEO and co‑founder

Dominique Surinx

CEO and co‑founder

Dominique leads Ansana and is responsible for overall strategy, financing and execution. He brings experience from the pharmaceutical and manufacturing industries, combined with entrepreneurial and supply‑chain expertise. This background helps him bridge clinical needs, operational realities in hospitals and the demands of bringing new hardware to market. Dominique has also invested a significant amount of his own capital into Ansana, which closely aligns his interests with those of external shareholders in this round.

Arnoud van den Berge Chief Commercial Officer

Arnoud van den Berge

Chief Commercial Officer

Arnoud is responsible for commercial strategy, sales and key customer relationships. He has worked for many years in the medical‑device industry, with a focus on selling complex solutions into hospital and clinical environments. This gives him practical insight into how purchasing decisions are made in hospitals and what is needed to move from pilot projects to broader roll‑outs. At Ansana, he focuses on building the commercial pipeline, shaping the value proposition with early customers and preparing the company for scale.

Stef Vanquickenborne Chief Technology Officer

Stef Vanquickenborne

Chief Technology Officer

Stef leads technology and product development. He brings more than 30 years of experience in research and development, industrial process technology and production environments. This is important for making Ansana’s smart hardware robust enough for demanding sterilisation conditions and for preparing the system for larger‑scale deployment. Stef oversees the technical roadmap for the first and second product generations and works closely with external development partners and suppliers.

Advisory Board

Ansana's advisory board brings together experienced industry and clinical voices to support the company's strategy, commercial development and product roadmap. The board combines deep medtech industry experience, clinical expertise from the operating room and a strong network in the global healthtech ecosystem.

first name last name, position

Martin Wenderoth

Advisory Board Member

Martin spent 25 years at B. Braun, one of the world's leading providers of healthcare and medical devices, including solutions for sterile processing and surgical care. He brings a business-focused perspective and deep knowledge of the global market Ansana is entering. Martin holds a PhD in Economics and supports Ansana in building the commercial foundations to become a global standard in surgical instrument management.

first name last name, position

Bruno Podesser

Advisory Board Member

Bruno is a practising heart surgeon at the university clinic in St. Pölten, Austria, and heads the Centre of Biomedical Research and Translational Surgery at the Medical University of Vienna. His clinical perspective from the operating room gives Ansana direct insight into the daily realities of surgical instrument management and the patient-safety implications of sterile processing. Bruno bridges the gap between clinical practice and product development.

first name last name, position

Pieter Wijfels

Venture Partner

Pieter brings 15 years of experience at Philips, where he worked on bringing healthcare innovations to market across the globe. He is now a Venture Partner at NLC, the venture builder behind Ansana. His combination of large-scale medtech experience and early-stage investment perspective makes him a valuable sounding board for Ansana's commercial and strategic decisions.

Company structure

Ansana has a simple group structure. The Dutch company Ansana B.V. is the parent and legal issuer in this round. It owns the technology, the Stryker patent licence and 100% of the shares in the US subsidiary Ansana Inc. Future US customer contracts, such as Tanner Health, are expected to be signed by Ansana Inc., with the economic value flowing back to Ansana B.V. 

Parent company

Ansana B.V. (Netherlands)

Dutch parent company and issuer in this round. Holds the technology, the Stryker patent licence and all shares in Ansana Inc.

Ansana Inc. (US)

Wholly owned US subsidiary. Planned contracting entity for US customers, including the Tanner Health pilot and later roll-outs.

Distribution of company shares

Ansana combines founder ownership with specialist healthtech funds and strategic partners. The company was created within the NLC venture builder, so NLC-related funds are key shareholders. The founding team, including the CEO, has also invested its own capital. In addition, a US health system (through Tanner / Healthliant) and several business angels are shareholders. Investors in this round subscribe to ordinary shares in Ansana B.V. on the same economic terms and share class as the most recent seed round.

# Shareholder Type Ownership
1 NLC Ventures
Healthtech venture builder fund. Largest shareholder because Ansana was created within the NLC venture platform.		 Healthtech venture fund 31.3%
2 NLC Health Impact Fund
Lead investor in the seed round. Focused on health-impact companies with scalable technology.		 Impact investment fund 8.1%
3 Stepping Stone Fund
NLC-managed fund that invested in earlier financing rounds and supports Ansana's growth.		 Healthtech investment fund 14.0%
4 Founders and management
Includes CEO Dominique Surinx and related entities. Founders have invested their own capital and hold a significant stake.		 Founders / management 18.7%
5 Tanner / Healthliant
Strategic US partner and shareholder connected to the Innovation Participation Agreement and pilot at Tanner Health.		 Strategic investor (health system) 10.0%
Other shareholders
Includes a regional governmental investment fund (LIOF), BGO (software-development partner investing via a STAK) and several business angels, each holding less than 10% of the shares.		 Other investors and partners 17.9%

Note: the cap table is shown on a fully diluted basis, assuming exercise of the outstanding warrants and conversion of the convertible loan from LIOF (€451,000), showing the situation before the current round on Invesdor.

Use of funds/funding scenarios

The final use of funds depends on how much is raised in this round. The total equity seed-extension is planned between €700,000 and €1,100,000. Anchor investors have together committed about €400,000, and between €300,000 and €700,000 is expected to come through the crowd investors.

In all scenarios, the funds will be used to complete the first-generation platform, execute the Tanner pilot in the United States and build a focused commercial pipeline. Higher funding mainly extends runway, adds sales capacity and gives Ansana more flexibility for the timing and terms of the next funding round.

Minimum scenario

Scenario I: approx. €700,000

Minimum total funding with full anchor commitment and minimum Invesdor participation. Focused on completing the first-generation product and reaching the Tanner proof point.

Invesdor investors €300,000
Anchor investors (committed) €400,000
Total funding ≈ €700,000

Use of funds

  • 60% — research and development, including Gen 1 completion and Tanner pilot integrations.
  • 15% — sales and marketing to support the Tanner relationship and a focused US pipeline.
  • 10% — operations, quality and regulatory work linked to pilot execution.
  • 15% — general and administrative costs for the team during the pilot period.

Maximum scenario

Scenario II: approx. €1,100,000

Maximum planned Invesdor participation together with the full anchor commitment. Extends runway, strengthens the commercial pipeline and improves the conditions for a future Series A.

Invesdor investors €700,000
Anchor investors (committed) €400,000
Total funding ≈ €1,100,000

Use of funds

  • 60% — research and development, including expanded product work and roadmap towards Gen 2.
  • 15% — sales and marketing to build a broader US and international pipeline beyond Tanner.
  • 10% — operations, quality and regulatory resources to support additional pilots or early roll-outs.
  • 15% — general and administrative costs plus contingency to extend runway and improve Series A timing.

Financial figures & growth

Actual and planned figures

Get an insight in to the company's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Login Sign up

Valuation & Exit

Company valuation

€5.9 million

This equity seed-extension round is priced at the same share price as the September 2025 seed round, establishing a pre-money valuation of €5.9 million on a fully diluted basis for Ansana B.V. Investors in this round subscribe to ordinary shares in the same share class and at the same price per share as existing shareholders.

Pre-money valuation (non-diluted)

≈ €5.3 million

Pre-money valuation (fully diluted)

≈ €5.9 million

The round is priced at a pre-money valuation of €5.332 million (non-diluted) and €5.904 million (fully diluted). This is the same share price as in the September 2025 seed round, reflecting a seed-extension structure rather than an uplift. The price per share is €27.54.

Because Ansana B.V. has granted 13,359 warrants, the fully diluted pre-money valuation is calculated using the treasury stock method, which is a standard way to take these warrants into account. Under this method, the cash proceeds from the warrants (exercise price €18.49) are assumed to be used to repurchase shares, resulting in 4,390 net additional shares and a fully diluted share count of 198,008 shares. Additionally, it is intended that the convertible loan of LIOF of ~450,000 is converted into equity before the closing of the Invesdor round. This increases the fully diluted share count to 214,392. A more detailed explanation of this calculation is provided in the Overview section above.

The valuation reflects Ansana's current stage, intellectual property, development progress and the strategic importance of the Tanner pilot as the next key proof point. Ansana and its investors expect the company to grow in value as technical and commercial milestones are reached over the coming years.

Fundraising history

Since 2022, Ansana has raised a mix of convertible loans, equity and shareholder loans to build the platform and prepare for the Tanner pilot. The main equity step-up took place in the September 2025 seed round at a pre-money valuation of €3,500,000. The current seed-extension round uses the same share price as that seed round. In addition, Ansana has been awarded a number of non-dilutive grants to support its research and development.

# Year / round Amount Type Company valuation*
1 December 2022 – initial financing
Stepping Stone Fund (convertible), shareholder loan from Dominique Surinx		 €175,000 €100,000 convertible loan (CLA), €75,000 subordinated shareholder loan N/A
2 May / August 2023 – debt funding
Rabobank, LIOF		 €500,000 €150,000 subordinated bank loan, €350,000 convertible loan (CLA) N/A
3 July 2024 – equity round
Stepping Stone Fund		 €350,000 Equity €1,850,000 pre-money
4 September 2025 – seed round
Stepping Stone Fund, NLC Health Impact Fund, Healthliant Ventures, Dominique Surinx, Peter Hermans and other investors		 €1,580,000 Equity €3,500,000 pre-money
# Year / grant Amount Type
1 2023 – MIT feasibility grant €20,000 Non-dilutive grant
2 2024 – MIT feasibility grant €20,000 Non-dilutive grant
3 2025 – Crossroads grant €250,000 Non-dilutive grant
4 2026 – Eurostars grant €820,000 Non-dilutive grant, paying approximately €100,000 per quarter until October 2027
Fundraising plan

With this equity seed-extension round, Ansana aims to finance completion of its first-generation platform, execution of the Tanner pilot in the United States and a focused commercial pipeline. The company expects this round, together with existing grants and planned non-dilutive funding, to provide enough runway to reach the “Tanner proof point” and prepare for a larger Series A round and related market launch..

The current plan is to raise approximately €800,000–€1,100,000 in equity now, alongside an already awarded Eurostars grant of about €820,000 paid over time. For 2027, management also targets additional grants and contract-based senior loans to complement equity and extend runway; these future grants and loans are not yet committed. If the Tanner pilot is successful and early commercial traction develops as planned, Ansana intends to raise a Series A round after the pilot to scale deployment across multiple hospital systems. The timing, size and terms of any future round will depend on progress, market conditions and investor interest.

Exit scenarios

For equity investors, returns typically come from a future sale of the company or a similar ownership event. Ansana and its current investors see a strategic acquisition as the most realistic path once the technology has been validated in daily use and recurring revenue has started to grow. The scenarios below outline the main possibilities from today's perspective and are illustrative only.

Most likely route

Sale to a hospital-operations or sterile-processing specialist

The most realistic exit route is a sale of Ansana to a strategic buyer focused on hospital operations, sterile processing, surgical instruments or operating-room efficiency. This could include companies that make sterilisation equipment, manage surgical instruments or provide hospital IT and traceability platforms. For such buyers, a proven real-time instrument-flow solution with reference hospitals and growing recurring revenue could be a natural extension of their portfolio.

Timeline: typically 5–7 years, assuming successful Tanner pilot, repeatable deployments and growing recurring revenue.

Strategic platform play

Integration into a broader medtech or digital-health platform

Another potential route is an acquisition by a larger medtech or digital-health group that wants to offer a more complete solution around operating-room and instrument workflows. This could include players in surgical instruments, implants or hospital IT that see value in combining their existing products with Ansana's real-time data and analytics. The Stryker licence and Ansana's patent position may also be relevant in this context, although there is no predefined acquisition obligation.

Timeline: similar 5–7-year horizon, depending on clinical validation, scale of deployment and strategic fit for buyers.

Alternative routes

Growth-equity investor or longer-term independence

If Ansana builds a strong base of recurring revenue and a growing network of hospital customers, a financial investor such as a growth-equity or healthcare-focused fund could provide larger follow-on funding instead of an early strategic sale. In this case the company could continue operating independently for a longer period, with a later exit through a strategic sale or other transaction. An initial public offering would require substantially more scale and is considered less likely at this stage.

Timeline: depends on revenue scale and investor interest; may extend beyond the 5–7-year horizon.

What could drive exit value

Potential exit value will depend mainly on how far Ansana progresses on a few key dimensions: successful Tanner pilot conversion, repeatable deployment across multiple hospital environments, growing hardware-enabled recurring revenue and a clear regulatory path for the second-generation product.

Market conditions and buyer appetite at the time of any transaction will also matter. There is no guarantee that any exit will occur, or that it would happen at a particular time or valuation.

Back to top ▲

Risks

Risks

Investing in early-stage companies through an equity investment is very high risk. You can lose part or all of the money you invest.

The following text is a short and strongly simplified overview of selected risks of an investment in Ansana B.V..

It is not complete and does not replace the detailed description of risks in the Key Investment Information Sheet (KIIS).

Before you invest, you must read the KIIS in full and with care and check whether you can understand and bear all of the risks described there.

If there are any differences between this summary and the KIIS, only the KIIS is legally binding.

Key Risk Areas (Short Overview)

Business, technology and management risk. Ansana is an early-stage company and has not yet generated revenue. Its pilot with Tanner Health / Healthliant Ventures may not lead to a commercial rollout. The technology must work reliably in a live hospital, and customers must accept new workflows. Delays, technical problems, supply-chain issues or the loss of key people could slow growth and increase costs.

Market, regulation and funding risk. Hospitals may have long purchasing, IT, security and approval processes. Market demand may therefore not lead to sales as quickly as expected. Healthcare, data-protection and product requirements may cause extra costs or delays. Ansana also depends on its Stryker licence. It may need more funding, which may not be available or may be available only on unfavourable terms.

Default, return and liquidity risk. If Ansana does not have enough cash, cannot carry out its plan or becomes insolvent, you may lose all of your investment. Forecasts and the company valuation are uncertain. Returns may be lower than expected, delayed or not paid at all. Profits may be kept in the company, so dividends may be limited or not paid. The depositary receipts are not traded on an organised market and can be difficult to transfer or sell, possibly only at a loss.

Investor rights, structure and platform risk. You invest indirectly through a STAK and receive depositary receipts, not direct shares. You have no direct voting rights. Future financing can dilute your economic stake. Tag-along, drag-along or buy-out provisions may lead to a sale at a time or on terms you do not expect. The crowdfunding platform may be unavailable or cease operating, which could delay subscriptions, payments or refunds.

A complete and detailed description of all risk factors can be found only in the KIIS in the documents section of this funding round.

Back to top ▲

-----End of marketing content-----

Documents

Investment related documents

Log in for more information.

Login Sign up

Updates

Note:

In this update section you will find new, project-relevant information that we receive.

Invesdor does not conduct a separate review of information received after the start of the financing phase.

UPDATE on 06.10.2026

€3 trillion. That’s the size of the global surgical market.

That is a huge market. But how much of it can Ansana realistically address?

Ansana focuses on a specific bottleneck within hospitals: limited operating room capacity. By tracking surgical instrument sets in real time, Ansana helps hospitals reduce delays and make better use of their existing operating room capacity.

For an average US hospital with 18 operating rooms, Ansana estimates a contract value of approximately €820,000 over five years, including around €107,000 in recurring annual revenue.

Market interest is also becoming increasingly concrete. Ansana currently has 22 potential customers in its pipeline, with the 10 most advanced opportunities together representing a potential contract value of €7.05 million.

The first pilot also has potential to develop into a commercial partnership. Tanner Health, the US healthcare group where the pilot is taking place, is also an investor in Ansana. If the pilot is successful, the partnership has a potential minimum value of $1 million.

The €3 trillion market is therefore the starting point. Within this market, Ansana is addressing a concrete problem with clear economic value for hospitals.

Invesdor is a Eurocrowd platform member.

Ausgezeichnet als Top-Innovator 2021

Winner of the Golden Bull as the best
Crowdfunding platform 2023.

ECSP lizensiert

Invesdor is licensed under the
ECSP regulation of the EU.